Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Libuše, Kabieszová"'
Autor:
Luděk, Rožnovský, Jakub, Mrázek, Lenka, Petroušová, Irena, Orságová, Libuše, Kabieszová, Michaela, Konečná, Alena, Kloudová
Publikováno v:
Klinicka mikrobiologie a infekcni lekarstvi. 26(3)
In a group of 211 patients with chronic hepatitis C treated with direct-acting antivirals, four experienced therapy failure. Two patients, one originally treated with dasabuvir/ombitasvir/paritaprevir/ritonavir and the other with glecaprevir/pibrenta
Autor:
Luděk, Rožnovský, Libuše, Kabieszová, Jakub, Mrázek, Alena, Kloudová, Lenka, Petroušová, Irena, Orságová, Michaela, Konečná
Publikováno v:
Klinicka mikrobiologie a infekcni lekarstvi. 24(4)
Vertical hepatitis C virus (HCV) transmission and persistence of anti-HCV antibodies were retrospectively investigated since 1999 in a group of 244 children whose mothers had a history of hepatitis C.Initial examinations performed in most children at
Autor:
Irena, Orságová, Luděk, RoŽnovský, Lenka, Petroušová, Michaela, Konečná, Libuše, Kabieszová, Jan, Martinek, Alena, Kloudová, Ladislav, Pavliska
Publikováno v:
Klinicka mikrobiologie a infekcni lekarstvi. 22(2)
To determine the prevalence of autoimmune parameters in patients with chronic hepatitis B and C (HBV, HCV) treated with conventional or pegylated interferon alpha (IFN) and monitor the development of autoimmune diseases in connection with this treatm
Autor:
Irena, Orságová, Luděk, RoŽnovský, Lenka, Petroušová, Michaela, Konečná, Libuše, Kabieszová, Kristian, Šafarčík, Alena, Kloudová
Publikováno v:
Klinicka mikrobiologie a infekcni lekarstvi. 20(3)
To determine the incidence of thyroid dysfunction in patients with chronic hepatitis B and C (HBV, HCV) who were treated with interferon (IFN) alpha.In the years 1992-2013, parameters of the thyroid gland were evaluated in 304 patients (256 with HCV,
Autor:
Luděk, Rožnovský, Irena, Orságová, Lenka, Petroušová, Josef, Tvrdík, Libuše, Kabieszová, Martin, Rydlo, Ivo, Lochman, Alena, Kloudová
Publikováno v:
Klinicka mikrobiologie a infekcni lekarstvi. 16(5)
Hepatitis B vaccination was started in 41 patients with end-stage liver disease who were liver transplant candidates. Patients received three 20 microg or, starting from 1999, 40 microg doses of recombinant vaccine at 0, 2 and 4 weeks. Blood samples